Abstract
Drug prices are innately dynamic, yet conventional economic evaluation assumes a constant price over time. Some healthcare technology assessment agencies, including the Institute for Clinical and Economic Review, do permit the inclusion of life-cycle drug pricing (LCDP) under certain circumstances. However, little guidance is given when this should be implemented and how it should be done. Our aim was to identify methods of incorporating LCDP into cost-effectiveness models, and characterize the current state-of-the-art.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
